Suggested remit: To appraise the clinical and cost effectiveness of atogepant within its marketing authorisation for treating migraine.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6615
Provisional Schedule
- Expected publication:
- 09 July 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- AbbVie (atogepant)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Action on Pain
- Brain and Spine Foundation
- Brain Charity
- Migraine Trust
- National Migraine Centre
- Neurological Alliance
- OUCH UK
- Pain Concern
- Pain Relief Foundation
- Pain UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Association of British Neurologists
- British Association for the Study of Headache
- British Geriatrics Society
- British Neuropathological Society
- British Pain Society
- Institute of Neurology
- National Neuroscience Advisory Group
- Neuromodulation Society of UK and Ireland
- Physiotherapy Pain Association
- Primary Care and Community Neurology Society
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Pfizer (rimegepant)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- Neurological Alliance of Scotland
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Wales Neurological Alliance
- Welsh Government
- Relevant research groups
- Brain Research UK
- Cochrane Pain, Palliative Care and Supportive Care Group
- Genomics England
- MRC Clinical Trials Unit
- National Hospital for Neurology and Neurosurgery
- National Institute for Health Research
- Pain Relief Foundation
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 January 2026 | Invitation to participate |
| 23 October 2025 - 20 November 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 23 October 2025 | In progress. Scoping commenced. |
| 18 August 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual